Inspira Technologies (IINN) announced a major milestone achievement in the in-vivo testing of its next-generation VORTX(TM) technology. This innovation is designed to oxygenate blood effectively without the trauma associated with conventional hollow fiber technologies. The in vivo testing achieved above 99% gas exchange target at a defined flow rate. “We are extremely proud to achieve this major technological milestone,” stated Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies. “I believe that the VORTX technology represents a significant leap forward in blood oxygenation, and successfully achieving this milestone within an IIA-funded framework underscores our team’s innovative capabilities and strengthens our commitment to advancing life-support technology.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IINN:
- Inspira Technologies Achieves First Revenue Milestone with INSPIRA ART100 Deployment
- Inspira generates first revenues from deployment of INSPIRA ART100 systems
- Inspira Technologies Expands Share Offering Capacity in April 2025
- Inspira Technologies Announces Extraordinary General Meeting for May 2025
- Inspira Technologies’ INSPIRA ART100 Achieves First Successful Patient Treatment